Ilsung Pharm (003120.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7003120003

Price
20,950.00 KRW
Market cap
150.04 bn KRW
P/E (2025)
128.70
P/S (2025)
2.33
Dividend yield
5.73 %
Net margin
1.81 %
Return on equity (ROE)
0.30 %
Return on assets (ROA)
0.29 %

Ilsung Pharm financials

Fiscal year20242025
Revenue69.02 bn KRW64.29 bn KRW
Gross profit27.05 bn KRW27.88 bn KRW
Operating income-3.25 bn KRW-6.16 bn KRW
EBIT11.20 bn KRW2.86 bn KRW
Net income13.09 bn KRW1.17 bn KRW
Diluted EPS – continuing operations1,921.18 KRW162.78 KRW

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Ilsung Pharm

Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular system products. The company was formerly known as Ilsung Pharmaceuticals Co., Ltd. and changed its name to Ilsung Is Co., Ltd. in April 2024. Ilsung Is Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.